

AMERICAN ACADEMY AND BOARD OF REGENERATIVE MEDICINE

From the Board of Directors



The AABRM Board of Directors has recently added several new members who bring an extraordinary level of knowledge and experience to the Board:

Carlos Cordon-Cardo, M.D., Ph.D., DABRM, FAARM is Professor and Chairman of the Department of Pathology at Mt. Sinai Health System. He is an internationally acclaimed expert in Cell and Molecular pathology with a subspecialty interest in Cancer Stem Cells.

Adolfo Firpo-Betancourt, M.D., MPA, DABRM, FAARM is Professor of Pathology at Mt. Sinai Health Systems with a subspecialty interest in Anatomic Pathology.

Diego Correa, M.D., M.Sc., Ph.D., DABRM, FAARM is an Assistant Professor at the University of Miami and Adjunct Assistant Professor at Case Western Reserve University. His specialty interest is in Musculoskeletal Regenerative Medicine.

Vasilis Paspaliaris, M.D., Ph.D., DABRM, FAARM from Melbourne Australia has been added as the President of the AABRM Asean Chapter.

AABRM Courses

The next **North American Board Certification Review Course and Written Examination** is in the planning stages for fall, 2017.



The **AABRM South America Chapter** will hold its second annual Board Certification course in Campinas, Brazil on May 3-5, 2017. The course is organized in conjunction with the **ORTHOREGEN** course series by the Instituto de Osso Cartilagem (IOC).



The **AABRM Europe Chapter** will hold its first annual Regenerative Medicine Review Course in Alexandroupolis, Greece in September, 2017.



The **AABRM Asia Chapter** had its first annual Regenerative Medicine Review Course and Symposium on December 17-18, 2016 in Kuala Lumpur, Malaysia.

Regulatory Update



Several new bills were recently introduced to congress, which could have a significant impact on the industry and practice of Regenerative Medicine:

On December 13, 2017, then President Obama signed the **21st Century Cures Act** into law. While this Act has far reaching general healthcare implications and provides for significant NIH funding to drive broad health care initiatives, there are several provisions which apply to Regenerative Medicine:

Section 3033 allows FDA to grant accelerated approval for Regenerative Medicine products **Section 3034** establishes that devices used with Regenerative Medicine products will be considered moderate risk devices unless other classification is required.

Section 3035 requires FDA to update guidance and regulations on Regenerative Medicine therapeutic products and hold public meeting to encourage innovation.

Section 3036 requires FDA do establish standards to support the development, evaluation and review of Regenerative Medicine and advanced therapies products.

